Clinical trials: sponsored by Peking University
Ovarian Cancer, Fallopian Tube Cancers
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
This study is a prospective, multicenter, single-arm, open-label phase II clinical trial. It is planned to enroll 53 subjects with HER2-expressing (IHC 1+, 2+, or 3+) partially platinum-sensitive recurrent epithelial ovarian…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07843303
- Testing
- Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Peking University Cancer Hospital & Institute
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
This study is a multicenter, open-label, single-arm phase II clinical trial investigating the efficacy and safety of niraparib monotherapy maintenance in HRD-positive newly diagnosed advanced epithelial ovarian cancer (EOC)…
- Trial name
- BRAND (NCT06141265)
- Testing
- Niraparib
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Peking University Cancer Hospital & Institute
Ovarian Carcinoma, Fallopian Tube Carcinoma
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT06420973
- Testing
- RC48+carboplatin±bevacizumab
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cancer Patients Receiving Radiotherapy for Kidney Malignancies
Efficacy Evaluation of Modified Zhixiao Tongmai Ning in Preventing Radiation-Induced Kidney Injury
This prospective randomized controlled study evaluates the clinical efficacy of modified Zhixiao Tongmai Ning in preventing radiation-induced kidney injury in cancer patients.
- Trial name
- NCT07849088
- Testing
- Modified Zhixiao Tongmai Ning, Standard Radiotherapy Alone
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Peking University First Hospital
Cancer
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
This prospective, single-center, open-label study aims to evaluate the safety, biodistribution, and tumor imaging characteristics of the novel ACE1-targeted PET radiotracer 68Ga-DOTA-BPP in patients with confirmed or suspected…
- Trial name
- NCT06203119
- Testing
- 68Ga-DOTA-BPP, 18F-FDG
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University Cancer Hospital & Institute
Obesity; Chronic Kidney Disease; Albuminuria
Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio…
- Trial name
- NCT07849348
- Testing
- Finerenone, Semaglutide
- Volunteers
- 266 people
- Sponsor
- Peking University People's Hospital
Alzheimer's Disease (AD)
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
- Trial name
- MOIPAD (NCT06924359)
- Testing
- Multimodal Ophthalmic Imaging and plasma biomarker
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University First Hospital
Lung Cancer (NSCLC), Cervical Squamous Cell Cancer
Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
[18F]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors.
- Conditions
- Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer
- Trial name
- NCT07848243
- Testing
- 18F-FDG, [18F]F-PDL1-3
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Cancer Hospital & Institute
Alzheimer's Disease, Blood Biomarkers
Blood Biomarkers for Screening of Alzheimer's Disease
The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due…
- Trial name
- NCT06477484
- Testing
- Blood biomarker
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Breast Cancer (Early Breast Cancer)
A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer
This is a multicenter, open-label, randomized controlled trial. A total of 432 eligible patients with HER2-positive breast cancer will be enrolled after screening.
- Trial name
- SwithADC (NCT07844291)
- Testing
- A1811, THP
- Volunteers
- 432 people
- Sponsor
- Peking University People's Hospital
Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL)
The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）
This study aimed to develop the imaging-based IUPU-PPGL score and evaluate its ability to stratify surgical complexity and its association with perioperative outcomes.
- Conditions
- Risk Grading System, Pheochromocytoma and Paraganglioma (PPGL), Quantitative Assessment
- Trial name
- NCT07412158
- Testing
- observational diagnostic model development
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University First Hospital
Upper Tract Urothelial Carcinoma
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
This randomized, open-label, multicenter phase III study is designed to compare disitamab vedotin plus radiotherapy with gemcitabine plus carboplatin as adjuvant treatment in patients with HER2-expressing upper tract urothelial…
- Trial name
- LUXUS41 (NCT07498907)
- Testing
- Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2)
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Peking University First Hospital
Plasma Cell Disorders, Multiple Myeloma (MM)
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma.
- Trial name
- NCT07660939
- Testing
- GPRC5D-Targeted PET/CT Imaging
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Solid Tumor Malignancies, Hematologic Cancer
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
- Conditions
- Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer
- Trial name
- NCT07039474
- Testing
- 18F-G1
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Sjögren's Disease, Interstitial Lung Disease
Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease
This study aims to evaluate the efficacy Telitacicept in patients with primary Sjögren's Disease with interstitial lung disease
- Trial name
- NCT07843381
- Testing
- Telitacicept 160mg, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Pancreatic Carcinoma
Effects of Aromatherapy With Essential Oils on Anxiety and Depression in Perioperative Patients With Pancreatic Cancer
The objective of this study is to investigate whether aromatherapy essential oils are effective in alleviating anxiety and depression in participants undergoing perioperative pancreatic cancer treatment.
- Trial name
- NCT06833658
- Testing
- Experimental: Aromatherapy with essential oil intervention, Control Group 0.9% Isotonic Saline
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Peking University First Hospital
CKD, Renal Fibrosis
FAP-targeting PET/CT for Noninvasive Monitoring of Renal Fibrosis
Chronic kidney disease (CKD) is an irreversible change of kidney function and structure caused by many reasons. The main threat of CKD to human health is progressive renal function decline.
- Trial name
- NCT06563765
- Testing
- FAP-targeting PET/CT imaging will be performed on the enrolled patients.
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
Chronic Pelvic Pain
Clinical Observation on the Efficacy of Acupoint Force Therapy Devices in the Intervention of Chronic Pelvic Pain
The present study is a prospective,single-center, single-arm, pre-post control clinical trial conducted at Peking University Third Hospital.
- Trial name
- NCT07841171
- Testing
- EMMA Robot-assisted Tuina
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
System Lupus Erythematosus, Systemic Sclerosis (SSc)
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
This study primarily involves the use of BCT301, an anti-CD19 Chemically induced pluripotent stem cell (CiPSC)-derived CAR-iT cells, for the treatment of patients with refractory autoimmune diseases, aiming to evaluate its…
- Conditions
- System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis, Antiphospholipid Syndrome
- Trial name
- NCT07301164
- Testing
- BCT301
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University Third Hospital
Sclerosis, Systemic
Clinical Cohort Study of Systemic Sclerosis
Systemic sclerosis (SSc) is an autoimmune disease primarily characterized by fibrosis of the skin and internal organs. In 2018, SSc was included in China's "First Batch of Rare Disease Catalog." Compared with the well-established…
- Trial name
- NCT07836361
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University Third Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.